An AI model can accurately flag EGFR mutations in lung adenocarcinoma using routine pathology slides, reducing the need for rapid genetic tests.
Key Details
- 1Researchers from Mount Sinai, Memorial Sloan Kettering, and collaborators published results in Nature Medicine on July 9, 2025.
- 2The AI model predicts EGFR mutations from H&E-stained pathology slides of lung adenocarcinoma.
- 3A live 'silent trial' at Memorial Sloan Kettering showed the model could reduce rapid genetic testing by over 40%.
- 4The model was trained and validated on the largest multi-institutional dataset of matched slides and sequencing results from the US and Europe.
- 5Preserving tissue by avoiding unnecessary rapid tests allows for more comprehensive genomic sequencing.
- 6Work is ongoing to broaden the model's biomarker detection and deploy it in more healthcare settings.
Why It Matters
This study demonstrates the practical integration of AI in pathology workflows, expediting precision therapy decisions and optimizing tissue usage in lung cancer diagnostics. It signals a major step toward AI-driven personalization in oncology, with potential to improve both efficiency and patient outcomes.
Source
EurekAlert
Related News
•EurekAlert
MD Anderson Unveils New AI Genomics Insights and Therapeutic Advances
MD Anderson reports breakthroughs in cancer therapeutics and provides critical insights into AI models for genomic analysis.
•EurekAlert
UCLA Researchers Present AI, Blood Biomarker Advances at SABCS 2025
UCLA Health researchers unveil major advances in breast cancer AI pathology, liquid biopsy, and biomarker strategies at the 2025 SABCS.
•EurekAlert
SH17 Dataset Boosts AI Detection of PPE for Worker Safety
University of Windsor researchers released SH17, a 8,099-image open dataset for AI-driven detection of personal protective equipment (PPE) in manufacturing settings.